Lupin Q1 FY24 Growth Metrics and ESG Goals
Lupin's ESG goals
In the context of double materiality, our goals are aligned to material topics impacting both enterprise value & environment/society
Product Accessibility
and Affordability
Access to Medicines
Targeting 80+ registrations of
anti-TB and ARV medicines in
2024
Implementation of Patient
Assistance Programs
Two programs by 2025, each
benefitting 100,000 patients
Education for Patients and Doctors
Touching 1 million Patients by
2028 and 20,000 doctors by
2030
Local Manufacturing
Partnership
Developing partnerships in
African firm by 2027 to
improve accessibility
Innovation
Management
Complex Generics: Launches in
Regulated Markets by 2028
.
20 complex product
launches in the areas of
inhalation, injectables,
among others
Biosimilar and Novel
Complex Products
•
•
Complete 3 biosimilar
filings in regulated
Regulatory Compliance,
Quality, and Patient Safety
Regulatory Compliance
Zero sites with Warning Letter
status (WL) by FY25
Recalls
.
Maintain zero class I recalls
Data Integrity
.
No data integrity-related
observations in any
markets by 2028
Launch 10 novel complex
pipeline products in India
by 2028
Process/Open Innovations
Target 15-20 process
innovations annually,
regulatory audits
Quality Audits
Lupin's India sites undergo
annual audits, while supplier
•
Patient
Centricity
Diagnosis
.
By 2030, assist in the diagnosis of
lung disease using fractional
exhaled nitric oxide (FENO) and
Spirometry tests for more than 1
million patients
Target the diagnosis of breast
cancer in 1,400 women in FY24
Rehabilitation
"Lungs on Care" campaign: Provide
in-clinic services for Interstitial Lung
Diseases (ILD) rehabilitation in 300
clinics by 2030
Atharv Ability, our neuro
rehabilitation center is targeting
an outreach to 10,000 patients in
sites are audited every three
years and during vendor
qualification
•
CGMP Training
resulting in $2-3 million in
savings
.
Ensure 100% completion of
mandatory training to
Full care
•
Pursue open innovation
applicable employees
FY24
Environmental
Stewardship
Greenhouse Gas Emissions
•
LUPIN
By 2030, reduce Scope 1 and
Scope 2 GHG emissions by
15% from 2019-20 levels
Water Conservation
·
By 2025, we aim to recycle
50% of our total water
withdrawal
Hazardous Waste
Management
•
By 2025, re-direct 60% of
incinerable hazardous waste
from Indian operations to
co-processing such as
cement plants
Regularly review and revise goals
In alignment with our
decarbonization strategy and
Scope 3 reduction objectives
Material Issues
Accessibility and
Affordability
Community Development
and CSR
partnerships in API,
formulations, digital
solutions, and diagnostics
Material Issues
Innovation Management and
Research
Digitization
Material Issues
Regulatory Compliance, Consumer
and Patient Safety &
Pharmacovigilance
Data Integrity, Data Privacy and
Cyber Security
Lyfe provides post ACS (acute
coronary syndrome) patient
care, aiming to reach 25,000
patients in FY24
Regulatory Compliance, Consumer and
Patient Safety & Pharmacovigilance
•
Material Issues
Environmental Impact
Management
Climate Change and Impact on
Business
Opportunities in Renewable Energy
Opportunities in Green Building
Material Issues
Community Engagement and
Development
Antimicrobial Resistance
Note: For further details, refer Integrated Report FY23:
14View entire presentation